-
Novartis Strikes Deal with Argo Biopharma for Global Rights to siRNA Drug Candidates
•
Argo Biopharma, a Shanghai-based developer of small interfering RNA (siRNA) drugs, has secured a licensing agreement with Novartis (NYSE: NVS), the Swiss pharmaceutical giant. The deal grants Novartis global rights to a Phase I drug candidate and ex-Greater China rights to another program currently in Phase I/IIa. In return, Argo…
-
Shanghai’s Argo Biopharma Raises USD 41 Million in Series A+ Financing Round
•
Shanghai-based siRNA drug developer Argo Biopharma has reportedly secured RMB 300 million (USD 41 million) in a Series A+ financing round. The investment round was led by SDIC China Merchants Investment, with additional contributions from Huagai Capital, Yuanxi Haihe Fund, and existing investor Trinity Innovation Fund. The funds will be…
